Published in Calcif Tissue Int on June 03, 2011
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Recommendations for preventing fracture in long-term care. CMAJ (2015) 1.62
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J Cell Physiol (2013) 1.04
A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2013) 0.97
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag (2012) 0.97
Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int (2013) 0.93
The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr Rheumatol Rep (2013) 0.92
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone (2012) 0.87
High-dose diosgenin reduces bone loss in ovariectomized rats via attenuation of the RANKL/OPG ratio. Int J Mol Sci (2014) 0.84
Treatment with Rhizoma Dioscoreae extract has protective effect on osteopenia in ovariectomized rats. ScientificWorldJournal (2014) 0.81
Osteogenic potential of punica granatum through matrix mineralization, cell cycle progression and runx2 gene expression in primary rat osteoblasts. Daru (2014) 0.81
Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab (2014) 0.81
Pulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/β-catenin signaling-associated mechanism. PLoS One (2013) 0.80
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). J Bone Miner Metab (2015) 0.79
Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf (2014) 0.78
Evaluation of fracture risk and fracture prevention: an Italian picture. Clin Cases Miner Bone Metab (2012) 0.78
The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. Osteoporos Int (2016) 0.78
Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday. HSS J (2015) 0.77
Systemic treatment with pulsed electromagnetic fields do not affect bone microarchitecture in osteoporotic rats. Int Orthop (2012) 0.77
Osteoporosis Treatment: When to Discontinue and When to Re-start. Bone Res (2013) 0.76
Moderate-intensity rotating magnetic fields do not affect bone quality and bone remodeling in hindlimb suspended rats. PLoS One (2014) 0.76
The protective effect of Rhizoma Dioscoreae extract against alveolar bone loss in ovariectomized rats via regulating Wnt and p38 MAPK signaling. Nutrients (2014) 0.76
Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. Osteoporos Int (2015) 0.75
Bone-Fat Interaction. Endocrinol Metab Clin North Am (2016) 0.75
Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Front Pharmacol (2016) 0.75
Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis (2017) 0.75
Hypocalcaemia after denosumab in older people following fracture. Osteoporos Int (2016) 0.75
Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford) (2017) 0.75
Effects of combined therapy of alendronate and low-intensity pulsed ultrasound on metaphyseal bone repair after osteotomy in the proximal tibia of aged rats. J Bone Miner Metab (2013) 0.75
Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. Clin Rheumatol (2014) 0.75
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (2004) 21.39
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg (2009) 8.79
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 7.09
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Osteoporosis. Lancet (2006) 5.40
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ (2010) 4.92
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int (2008) 3.80
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA (2010) 3.37
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab (2010) 2.70
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol (2002) 2.55
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol (2006) 2.52
Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone (2009) 2.44
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol (2008) 2.24
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc (2002) 1.97
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf (2009) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
An overview of drug-induced acute kidney injury. Crit Care Med (2008) 1.64
Provision of information about drug side-effects to patients. Lancet (2002) 1.62
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) (2009) 1.60
Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf (2003) 1.59
Risks and benefits of bisphosphonates. Br J Cancer (2008) 1.57
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause (2003) 1.56
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol (2004) 1.52
Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res (2003) 1.46
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause (2009) 1.42
Osteonecrosis of the jaw and bisphosphonates. BMJ (2010) 1.41
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci (2003) 1.38
Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int (2009) 1.38
Bisphosphonate-associated adverse events. Hormones (Athens) (2009) 1.36
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
Cost-equivalence of different osteoporotic fractures. Osteoporos Int (2003) 1.33
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 1.29
Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod (2002) 1.23
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol (2004) 1.22
Osteoporosis treatments and adverse events. Curr Opin Rheumatol (2009) 1.20
Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf (2009) 1.18
Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg (2010) 1.18
Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol (2007) 1.17
Osteosarcoma and teriparatide? J Bone Miner Res (2007) 1.14
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt) (2009) 1.12
Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol (2001) 1.10
Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol (2007) 1.10
Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf (2007) 1.08
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc (2002) 1.07
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res (2005) 1.06
Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin (2005) 1.05
Adverse effects of bisphosphonates. Calcif Tissue Int (2010) 1.04
Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs (2000) 1.03
Safety of bisphosphonates in the treatment of osteoporosis. Am J Med (2009) 1.02
Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res (2010) 1.02
Teriparatide: a review of its use in osteoporosis. Drugs (2008) 1.00
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord (2009) 0.98
Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res (2009) 0.97
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke (2008) 0.97
Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin (2005) 0.97
Denosumab-related osteonecrosis of the jaws. Osteoporos Int (2010) 0.94
The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int (2009) 0.91
Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact (2007) 0.90
Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas (2000) 0.85
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int (2009) 0.85
Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM (2011) 0.84
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Effect of in utero and early-life conditions on adult health and disease. N Engl J Med (2008) 14.46
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Osteoporosis. Lancet (2006) 5.40
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Using natural experiments to evaluate population health interventions: new Medical Research Council guidance. J Epidemiol Community Health (2012) 4.26
Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Cohort profile: The Southampton Women's Survey. Int J Epidemiol (2005) 4.11
Genome-wide association study identifies five loci associated with lung function. Nat Genet (2009) 4.10
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet (2008) 3.83
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol (2006) 3.36
Grip strength, body composition, and mortality. Int J Epidemiol (2006) 3.36
A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing (2011) 3.27
Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. Arthritis Rheum (2004) 3.24
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Epidemiology and treatment of painful procedures in neonates in intensive care units. JAMA (2008) 3.19
Epigenetic gene promoter methylation at birth is associated with child's later adiposity. Diabetes (2011) 3.18
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol (2002) 3.01
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Objective measures of physical capability and subsequent health: a systematic review. Age Ageing (2010) 2.78
The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 2.75
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73
Intelligence in childhood and chronic widespread pain in middle age: the National Child Development Survey. Pain (2012) 2.71
Does sarcopenia originate in early life? Findings from the Hertfordshire cohort study. J Gerontol A Biol Sci Med Sci (2004) 2.64
Epidemiology of hip fracture: Worldwide geographic variation. Indian J Orthop (2011) 2.60
Women's compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study. BMJ (2009) 2.54
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J Bone Miner Res (2003) 2.47
Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart (2010) 2.42
Vitamin D: some perspective please. BMJ (2012) 2.35
Developmental origins of midlife physical performance: evidence from a British birth cohort. Am J Epidemiol (2006) 2.35
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28
Postpartum maternal mortality and cesarean delivery. Obstet Gynecol (2006) 2.25
Osteoporosis: impact on health and economics. Nat Rev Rheumatol (2010) 2.25
Sensitivity of the bacterial meningitis score in 889 children with bacterial meningitis. J Pediatr (2007) 2.24
Is grip strength a useful single marker of frailty? Age Ageing (2003) 2.22
Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res (2012) 2.22
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom (2008) 2.21
Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women. J Bone Miner Res (2008) 2.20
Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos (2011) 2.14
Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med (2011) 2.07
Androgens and bone. Endocr Rev (2004) 2.06
Predictors of outcomes of total knee replacement surgery. Rheumatology (Oxford) (2012) 2.05
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care (2005) 2.03
Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res (2004) 2.01
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Epidemiology and burden of osteoarthritis. Br Med Bull (2013) 1.97
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Prediction of childhood obesity by infancy weight gain: an individual-level meta-analysis. Paediatr Perinat Epidemiol (2011) 1.93
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res (2010) 1.90
New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nat Genet (2012) 1.90
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke (2009) 1.88